Plain-English translation of NCT04832009 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This research study is testing whether (vitamin C) can help restore the health of your blood vessels and the nerves that control them. Researchers will temporarily raise your blood glucose or lipid levels using IV infusions, then test whether vitamin C can protect your vessels from damage. The goal is to understand whether this common, safe antioxidant might prevent long-term vascular problems.
High blood sugar and high cholesterol can damage blood vessels and the nerves controlling them, which contributes to high blood pressure and heart disease. This study wants to see if the medication might protect vessels from this damage, which could lead to new ways to prevent or reverse vascular injury in people at risk.
You likely qualify if…
You likely don't qualify if…
You would attend three study visits. At two of the visits, you'll receive an intravenous infusion that temporarily raises either your blood glucose or lipid levels. During the same infusion, you'll randomly receive either vitamin C or a placebo (inactive substance). Researchers will measure your blood vessel and nerve function before and after each infusion using specialized equipment, including a small microelectrode placed near your knee to safely record nerve activity. The entire study takes place over a few weeks.
AI-generated summary from trial data · Jun 22, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
University of Kansas Medical Center
Enrollment target
~46 participants
Started
May 2022
Primary completion
August 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 79 Years
Last updated on clinicaltrials.gov in June 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Seth W Holwerda, PhD
University of Kansas Medical Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.